Irish MedTech company, Neuromod Devices, introduces a tinnitus treatment device in Norway.

Neuromod Devices, an Irish medical device firm that specialises in tinnitus therapy, has secured an agreement with HØR AS, Norway’s leading private provider of hearing and tinnitus care, to bring its Lenire tinnitus treatment device to the Norwegian market.

Neuromod Devices was founded in 2010 and has operations in Co. Dublin. The company is backed up by a network of long-standing and well-known worldwide partners.

Tinnitus is a neurological disorder and is estimated to affect 10 to 15% of the adult population, which could mean that up to 650,000 Norwegians are affected. Lenire is a bimodal neuromodulation device that has been demonstrated to reduce the symptoms of tinnitus in clinical trials.

The agreement follows the launch of Lenire in Spain in early 2022 and the release of an independent real-world research verifying the device’s safety and efficacy in treating tinnitus symptoms. According to the study, 85 percent of tinnitus patients saw a reduction in their symptoms.